A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment is a phase 2/3 interventional study registered as NCT07490262, led by Innovent Biopharmaceutical Technology (Hangzhou), and recruiting on the registry. Official title: A Randomised, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma. Planned enrolment is 680 participants (estimated). The study started in 2026-03-27 and primary completion is expected in 2027-12-31. No results have been posted on ClinicalTrials.gov.